- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03358472
Pembrolizumab Plus Epacadostat, Pembrolizumab monoterapi og EXTREME-regimet ved tilbakevendende eller metastatisk hode- og nakkeplateepitelkarsinom (KEYNOTE-669/ECHO-304)
En fase 3 randomisert, åpen klinisk studie for å evaluere effektiviteten og sikkerheten til Pembrolizumab Plus Epacadostat, Pembrolizumab monoterapi og EXTREME-regimet som førstelinjebehandling for tilbakevendende eller metastatisk hode- og nakkeplateepitelkarsinom (KEYNOTE-6369/ECHO) )
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Chris OBrien Lifehouse
-
North Ryde, New South Wales, Australia, 2109
- Macquarie University Hospital
-
-
Queensland
-
Herston, Queensland, Australia, 4029
- Royal Brisbane & Women s Hospital
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Juravinski Cancer Center Hamilton Health Sciences
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Jewish General Hospital
-
Québec, Quebec, Canada, G1R 3S1
- CHU de Quebec-Universite Laval-Hotel Dieu de Quebec
-
-
-
-
California
-
Anaheim, California, Forente stater, 19026
- Pacific Cancer Medical Center
-
Sacramento, California, Forente stater, 95817
- UC Davis Comprehensive Cancer Center
-
Santa Rosa, California, Forente stater, 95403
- St. Joseph Heritage Healthcare
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- University of Colorado Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06520
- Yale Cancer Center
-
-
Georgia
-
Douglasville, Georgia, Forente stater, 30134
- Northwest Georgia Oncology Centers PC
-
-
Kansas
-
Westwood, Kansas, Forente stater, 66205
- U of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40223
- Baptist Health
-
-
Montana
-
Billings, Montana, Forente stater, 59102
- St. Vincent Healthcare Cancer Ctr
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87106
- New Mexico Cancer Care Alliance
-
-
Oklahoma
-
Tulsa, Oklahoma, Forente stater, 74146
- Oklahoma Cancer Specialists and Research
-
-
Oregon
-
Portland, Oregon, Forente stater, 97213
- Providence Portland Med Center
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 19026
- Huntsman Cancer Institute Univ of Utah
-
-
Washington
-
Seattle, Washington, Forente stater, 98101
- Viginia Mason Med Ctr
-
-
-
-
-
Milan, Italia, 20141
- Istituto Europeo di Oncologia
-
Rozzano, Italia, 20089
- IRRCS Instituto Clinico Humanitas
-
-
-
-
-
Akashi, Japan, 673-8558
- Hyogo Cancer Center
-
Fukuoka, Japan, 812-8582
- Kyushu University Hospital
-
Hiroshima, Japan, 734-8551
- Hiroshima University Hospital
-
Hokkaido, Japan, 060-8648
- Hokkaido University Hospital
-
Kobe, Japan, 650-0047
- Kobe City Medical Center General Hospital
-
Saitama, Japan, 362-0806
- Saitama Cancer Center
-
Sayama, Japan, 589-8511
- Kindai University Hospital
-
Shizuoka, Japan, 411-8777
- Shizuoka Cancer Center Hospital and Research Institute
-
Tokyo, Japan, 135-8550
- The Cancer Institute Hospital of JFCR
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-8577
- National Cancer Center Hospital East
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Japan, 920-8641
- Kanazawa University Hospital
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 241-8515
- Kanagawa Cancer Center
-
-
Miyagi
-
Natori-shi, Miyagi, Japan, 981-1293
- Miyagi Cancer Center
-
Sendai, Miyagi, Japan, 980-8574
- Tohoku University Hospital
-
-
-
-
-
Konin, Polen, 62-500
- Przychodnia Lekarska Komed
-
Szczecin, Polen, 71-730
- Zachodniopomorskie Centrum Onkologii
-
-
Masovian Voivodeship
-
Wieliszew, Masovian Voivodeship, Polen, 05-135
- Mazowiecki Szpital Onkologiczny
-
-
-
-
-
Coimbra, Portugal, 3000-075
- Inst. Portugues de Oncologia de Coimbra Frencisco Gentil EPE
-
Lisbon, Portugal, 1099-023
- Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE
-
Lisbon, Portugal, 1649-035
- Centro Hospitalar Lisboa Norte EPE - Hospital de Santa Maria
-
Porto, Portugal, 4200-072
- Inst. Portugues de Oncologia de Porto Francisco Gentil EPE
-
-
-
-
-
Badalona, Spania, 08916
- Hospital Germans Trias i Pujol. ICO de Badalona
-
Barcelona, Spania, 08035
- Hospital General Universitari Vall d Hebron
-
Madrid, Spania, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spania, 28034
- Hospital Ramon y Cajal
-
Madrid, Spania, 28981
- Hospital Infanta Cristina
-
Seville, Spania, 41014
- Hospital de Nuestra Senora de Valme
-
Zaragoza, Spania, 50009
- Hospital Clinico Lozano Blesa
-
-
-
-
-
London, Storbritannia, N18 1QX
- North Middlesex Hospital
-
London, Storbritannia, NW1 2PG
- University College London Hospitals (UCLH)
-
London, Storbritannia, SW3 6JJ
- The Royal Marsden Foundation Trust
-
London, Storbritannia, SW3 6JJ
- The Royal Marsden Nhs Foundation Trust - Chelsea
-
Taunton, Storbritannia, TA1 5DA
- Musgrove Park Hospital
-
-
-
-
-
Seoul, Sør -Korea, 03080
- Seoul National University Hospital
-
Seoul, Sør -Korea, 05505
- Asan Medical Center
-
Seoul, Sør -Korea, 03722
- Severance Hospital Yonsei University Health System
-
-
-
-
-
Tainan, Taiwan, 70457
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 10048
- National Taiwan University Hospital
-
Taoyuan, Taiwan, 33305
- Chang Gung Medical Foundation. Linkou
-
-
-
-
-
Adana, Tyrkia (Türkiye), 01370
- Adana Sehir Hastanesi
-
Ankara, Tyrkia (Türkiye), 06100
- Hacettepe Universitesi Tip Fakultesi Hastanesi
-
Edirne, Tyrkia (Türkiye), 22030
- Trakya Universitesi Tip Fakultesi
-
Istanbul, Tyrkia (Türkiye), 34093
- Istanbul Universitesi Onkoloji Enstitusu
-
Istanbul, Tyrkia (Türkiye), 34214
- Medipol Hastanesi
-
Izmir, Tyrkia (Türkiye), 35040
- Ege Universitesi Tip Fakultesi Hastanesi
-
Malatya, Tyrkia (Türkiye), 44280
- Inonu Universitesi Turgut Ozal Tip Merkezi
-
-
-
-
-
Miskolc, Ungarn, 3526
- Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz
-
Szolnok, Ungarn, 5000
- Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet
-
-
-
-
-
Salzburg, Østerrike, 5020
- Landeskrankenhaus Salzburg
-
Vienna, Østerrike, 1090
- Allgemeines Krankenhaus der Stadt Wien
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Measurable disease based on RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function per protocol-defined criteria.
- Documentation of results from testing of human papilloma virus (HPV) status for oropharyngeal cancer.
- Baseline archival tumor specimen available or willing to undergo a prestudy treatment tumor core or excisional biopsy of a tumor lesion not previously irradiated, to obtain the specimen.
Exclusion Criteria:
- Carcinoma of the nasopharynx, salivary gland, unknown primary origin, or nonsquamous histologies as primary tumors.
- Disease progression within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.
- Use of protocol-defined prior/concomitant therapy.
- Known additional malignancy that is progressing or has required active treatment within the past 3 years.
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Active autoimmune disease that has required systemic treatment in past 2 years.
- Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
- Known history of or is positive for active hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (defined as HCV RNA [qualitative] is detected).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Pembrolizumab
|
Pembrolizumab administered intravenously every 3 weeks.
Andre navn:
|
|
Eksperimentell: Pembrolizumab + Epacadostat
|
Pembrolizumab administered intravenously every 3 weeks.
Andre navn:
Epacadostat administered orally twice daily.
Andre navn:
|
|
Aktiv komparator: EXTREME
EXTREME regimen includes cetuximab + cisplatin or carboplatin + 5-fluorouracil. |
Cetuximab administered intravenously on Cycle 1 Day 1 followed by administration every week. Cisplatin administered intravenously every 3 weeks for </= 6 cycles. Carboplatin administered intravenously every 3 weeks for </= 6 cycles. 5-Fluorouracil administered intravenously every 3 weeks for </= 6 cycles. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate (ORR) of Pembrolizumab + Epacadostat, Pembrolizumab Monotherapy and the EXTREME Regimen
Tidsramme: Minimum Week 9
|
ORR was defined as the percentage of participants who had a complete response (CR), disappearance of all target lesions or partial response (PR), >=30% decrease in the sum of the longest diameter of target lesions per RECIST v1.1 by investigator determination. Responses are based on investigator assessments per RECIST 1.1 without confirmation using all available scans. |
Minimum Week 9
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety and Tolerability of Pembrolizumab + Epacadostat Versus Pembrolizumab Versus the EXTREME Regimen as Measured by Number of Participants Experiencing Adverse Events (AEs)
Tidsramme: up to approximately 8 years
|
AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. |
up to approximately 8 years
|
|
Safety and Tolerability of Pembrolizumab + Epacadostat Versus Pembrolizumab Versus the EXTREME Regimen as Measured by Number of Participants Discontinuing Study Treatment Due to AEs
Tidsramme: up to approximately 8 years
|
AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. |
up to approximately 8 years
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: Mark Jones, MD, Incyte Corporation
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Neoplasmer etter histologisk type
- Neoplasmer, kjertel og epitel
- Karsinom
- Karsinom, plateepitel
- Plateepitelkarsinom i hode og nakke
- Neoplasmer i hode og nakke
- Parkinsons sykdom 4, autosomal dominerende lewy kropp
- Aminosyrer, peptider og proteiner
- Proteiner
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Antistoffer, monoklonalt, humanisert
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Uorganiske kjemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Koordinasjonskomplekser
- Pyrimidiner
- Uracil
- Pyrimidinoner
- Platinumforbindelser
- Cetuximab
- Fluorouracil
- Karboplatin
- Cisplatin
- pembrolizumab
- Epacadostat
Andre studie-ID-numre
- KEYNOTE-669/ECHO 304
- 2017 (U.S. NIH-stipend/kontrakt)
- 2017-001338-24 (EudraCT-nummer)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .